Alumis (ALMS) to Post Earnings on Wednesday

Alumis (NASDAQ:ALMS) is anticipated to release its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.7290) per share and revenue of $3.4680 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The company had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. On average, analysts expect Alumis to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Alumis Stock Up 3.8%

NASDAQ:ALMS opened at $27.12 on Wednesday. Alumis has a twelve month low of $3.76 and a twelve month high of $31.35. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -13.70 and a beta of -0.69. The stock’s 50 day moving average price is $25.26 and its two-hundred day moving average price is $25.20.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Chardan Capital raised their target price on shares of Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, May 19th. Citigroup reaffirmed a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. Morgan Stanley reiterated an “overweight” rating and issued a $39.00 price target on shares of Alumis in a research note on Friday, May 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. Finally, Wall Street Zen lowered shares of Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.30.

Insider Activity

In other news, insider Sanam Pangali sold 5,000 shares of Alumis stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $28.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider directly owned 11,111 shares in the company, valued at approximately $311,108. The trade was a 31.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 33.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alumis

Large investors have recently added to or reduced their stakes in the business. MPM Bioimpact LLC acquired a new stake in Alumis during the 4th quarter valued at $23,443,000. Orbimed Advisors LLC acquired a new position in shares of Alumis in the second quarter valued at $5,779,000. Woodline Partners LP increased its holdings in shares of Alumis by 809.7% in the third quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock valued at $6,987,000 after purchasing an additional 1,558,660 shares during the last quarter. Samsara Biocapital LLC raised its position in shares of Alumis by 47.0% in the second quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after purchasing an additional 1,534,872 shares during the period. Finally, Millennium Management LLC raised its position in shares of Alumis by 263.1% in the fourth quarter. Millennium Management LLC now owns 1,151,118 shares of the company’s stock valued at $11,235,000 after purchasing an additional 834,089 shares during the period.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.